{
  "docId": "019de073-e127-72a6-a95e-e417b3ed6013",
  "docSlug": "0a46c3e8bf46013b57087adaac7a88f4",
  "documentTitle": "Xeris Biopharma | Investor Presentation Deck | 11 slides",
  "authorId": "xeris-biopharma",
  "authorName": "Xeris Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 11,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e127-72a6-a95e-e417b3ed6013/10",
  "deckHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013",
  "deckJsonHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013.json",
  "deckAnchorHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.91,
        "x": 0.045,
        "y": 0.25
      },
      "kind": "list",
      "text": "Large market opportunity: Oral levothyroxine is one of the most prescribed therapies in US with over 100 million prescriptions annually\nDemonstrated proof-of-concept: A once weekly subcutaneous injection of XP-8121 can provide comparable exposure to daily oral Synthroid® supporting further development in patients with congenital or acquired hypothyroidism who require thyroid hormone replacement\nDose conversion ratio established: Chronic dosing simulation implies dose conversion ratio of 4X\nSafe and well tolerated: XP-8121 in healthy volunteers was generally well tolerated at all doses\nNext Steps: FDA End-of-Phase 1 meeting requested; interaction expected by year-end",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6bc7580-be94-465e-b935-eb94ff6bbd75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.44,
        "x": 0.045,
        "y": 0.13
      },
      "kind": "title",
      "text": "XP-8121 Highlights and Next Steps",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "962329c3-6287-4e87-bb1c-c341144f5290",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "66138fc9-0919-4404-8cc7-48babd267bd8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "The key takeaways slide summarizes the main points.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f2a7b48c-76f2-4134-b42d-4dd72dd13ce4",
      "evidence": "The appendix methodology and key takeaways slides present the golden circle.",
      "position": 1,
      "objective": "How does XeriSol™ Levothyroxine work and what are the benefits?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}